These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 9815935)
21. P53 mutations and loss of heterozygosity on chromosomes 8p, 16q, 17p, and 18q are confined to advanced prostate cancer. Massenkeil G; Oberhuber H; Hailemariam S; Sulser T; Diener PA; Bannwart F; Schäfer R; Schwarte-Waldhoff I Anticancer Res; 1994; 14(6B):2785-90. PubMed ID: 7872719 [TBL] [Abstract][Full Text] [Related]
22. Definitive functional evidence for a tumor suppressor gene on human chromosome 7q31.1 neighboring the Fra7G site. Zenklusen JC; Hodges LC; LaCava M; Green ED; Conti CJ Oncogene; 2000 Mar; 19(13):1729-33. PubMed ID: 10763831 [TBL] [Abstract][Full Text] [Related]
23. Loss of heterozygosity analysis of a candidate gastric carcinoma tumor suppressor locus at 7q31. Xia JC; Weng DS; Li JT; Qin HD; Mai SJ; Feng BJ; Fan Q; Feng QS; Huang LX; Yu XJ; Pan ZZ; Li YQ; Wang QJ; Zhan YQ; Chen SP; He J; Huang WL; Wu PH; Zeng YX Cancer Genet Cytogenet; 2006 Apr; 166(2):166-72. PubMed ID: 16631475 [TBL] [Abstract][Full Text] [Related]
24. Identification of a I-cM region of common deletion on 13q14 associated with human prostate cancer. Ueda T; Emi M; Suzuki H; Komiya A; Akakura K; Ichikawa T; Watanabe M; Shiraishi T; Masai M; Igarashi T; Ito H Genes Chromosomes Cancer; 1999 Mar; 24(3):183-90. PubMed ID: 10451697 [TBL] [Abstract][Full Text] [Related]
25. Loss of heterozygosity in chromosomal region 16q24.3 associated with progression of prostate cancer. Härkönen P; Kyllönen AP; Nordling S; Vihko P Prostate; 2005 Feb; 62(3):267-74. PubMed ID: 15389780 [TBL] [Abstract][Full Text] [Related]
26. Loss of heterozygosity on chromosomes 10 and 17 in clinically localized prostate carcinoma. Ittmann MM Prostate; 1996 May; 28(5):275-81. PubMed ID: 8610052 [TBL] [Abstract][Full Text] [Related]
27. An LOH and mutational investigation of the ST7 gene locus in human esophageal carcinoma. Wang S; Mori Y; Sato F; Yin J; Xu Y; Zou TT; Olaru A; Kimos MC; Perry K; Selaru FM; Deacu E; Sun M; Shi YC; Shibata D; Abraham JM; Greenwald BD; Meltzer SJ Oncogene; 2003 Jan; 22(3):467-70. PubMed ID: 12545169 [TBL] [Abstract][Full Text] [Related]
28. LOH analyses in the region of the putative tumour suppressor gene C13 on chromosome 13q13. Fiedler U; Ehlers W; Meye A; Füssel S; Faller G; Schmidt U; Wirth MP Anticancer Res; 2001; 21(4A):2341-50. PubMed ID: 11724291 [TBL] [Abstract][Full Text] [Related]
29. Frequent deletions within FRA7G at 7q31.2 in invasive epithelial ovarian cancer. Huang H; Reed CP; Mordi A; Lomberk G; Wang L; Shridhar V; Hartmann L; Jenkins R; Smith DI Genes Chromosomes Cancer; 1999 Jan; 24(1):48-55. PubMed ID: 9892108 [TBL] [Abstract][Full Text] [Related]
30. Identification and characterization of proximal 6q deletions in prostate cancer. Cooney KA; Wetzel JC; Consolino CM; Wojno KJ Cancer Res; 1996 Sep; 56(18):4150-3. PubMed ID: 8797584 [TBL] [Abstract][Full Text] [Related]
31. Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression. Qian J; Hirasawa K; Bostwick DG; Bergstralh EJ; Slezak JM; Anderl KL; Borell TJ; Lieber MM; Jenkins RB Mod Pathol; 2002 Jan; 15(1):35-44. PubMed ID: 11796839 [TBL] [Abstract][Full Text] [Related]
32. Deletion at chromosome arms 6q16-22 and 10q22.3-23.1 associated with initiation of prostate cancer. Lu T; Hano H Prostate Cancer Prostatic Dis; 2008; 11(4):357-61. PubMed ID: 18227855 [TBL] [Abstract][Full Text] [Related]
33. Allelotyping analysis at chromosome 13q of high-grade prostatic intraepithelial neoplasia and clinically insignificant and significant prostate cancers. Lu W; Takahashi H; Furusato M; Maekawa S; Nakano M; Meng C; Kikuchi Y; Sudo A; Hano H Prostate; 2006 Mar; 66(4):405-12. PubMed ID: 16302266 [TBL] [Abstract][Full Text] [Related]
34. Genetic heterogeneity of surgically resected prostate carcinomas and their biopsy specimens is related to their histologic differentiation. Takimoto Y; Shimazui T; Akaza H; Sato N; Noguchi M Cancer; 2001 Jan; 91(2):362-70. PubMed ID: 11180083 [TBL] [Abstract][Full Text] [Related]
35. Defining the region(s) of deletion at 6q16-q22 in human prostate cancer. Hyytinen ER; Saadut R; Chen C; Paull L; Koivisto PA; Vessella RL; Frierson HF; Dong JT Genes Chromosomes Cancer; 2002 Jul; 34(3):306-12. PubMed ID: 12007191 [TBL] [Abstract][Full Text] [Related]
36. Definition and refinement of chromosome 8p regions of loss of heterozygosity in gastric cancer. Baffa R; Santoro R; Bullrich F; Mandes B; Ishii H; Croce CM Clin Cancer Res; 2000 Apr; 6(4):1372-7. PubMed ID: 10778965 [TBL] [Abstract][Full Text] [Related]
37. Loss of heterozygosity at 12P12-13 in primary and metastatic prostate adenocarcinoma. Kibel AS; Faith DA; Bova GS; Isaacs WB J Urol; 2000 Jul; 164(1):192-6. PubMed ID: 10840458 [TBL] [Abstract][Full Text] [Related]
38. Allelic loss and reduced expression of the ING3, a candidate tumor suppressor gene at 7q31, in human head and neck cancers. Gunduz M; Ouchida M; Fukushima K; Ito S; Jitsumori Y; Nakashima T; Nagai N; Nishizaki K; Shimizu K Oncogene; 2002 Jun; 21(28):4462-70. PubMed ID: 12080476 [TBL] [Abstract][Full Text] [Related]
39. An 800-kb region of deletion at 13q14 in human prostate and other carcinomas. Chen C; Frierson HF; Haggerty PF; Theodorescu D; Gregory CW; Dong JT Genomics; 2001 Oct; 77(3):135-44. PubMed ID: 11597138 [TBL] [Abstract][Full Text] [Related]
40. Allelic loss at 7q31.1 in human primary ovarian carcinomas suggests the existence of a tumor suppressor gene. Zenklusen JC; Weitzel JN; Ball HG; Conti CJ Oncogene; 1995 Jul; 11(2):359-63. PubMed ID: 7624150 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]